Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant - Reuters
AI Summary1 min read
TL;DR
Novo Nordisk's Alzheimer's drug trial failed, causing a sharp drop in its shares as the treatment did not meet key targets.
- Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant Reuters
- Novo Nordisk shares plunge to four-year low after Alzheimer's drug trial fails to hit key target CNBC
- Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials The Wall Street Journal
- Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says CNN
- Weight-loss drugs: What other conditions are they being used and tested for? Reuters